| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ... Blood, The Journal of the American Society of Hematology 112 (10), 4017-4023, 2008 | 516 | 2008 |
| Química da madeira U Klock, GIB Muñiz, JA HERNANDEZ, AS Andrade Fupef, Curitiba, 2005 | 359 | 2005 |
| Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases R García‐Sanz, S Montoto, A Torrequebrada, AG De Coca, J Petit, ... British journal of haematology 115 (3), 575-582, 2001 | 299 | 2001 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 298 | 2020 |
| Global retinoblastoma presentation and analysis by national income level ID Fabian, E Abdallah, SU Abdullahi, RA Abdulqader, SA Boubacar, ... JAMA oncology 6 (5), 685-695, 2020 | 267 | 2020 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 260 | 2020 |
| Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study J García-Suárez, J de la Cruz, Á Cedillo, P Llamas, R Duarte, ... Journal of hematology & oncology 13, 1-12, 2020 | 227 | 2020 |
| Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial SE Kasner, B Swaminathan, P Lavados, M Sharma, K Muir, R Veltkamp, ... The Lancet Neurology 17 (12), 1053-1060, 2018 | 183 | 2018 |
| Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia TJ González‐López, C Pascual, MT Álvarez‐Román, ... American journal of hematology 90 (3), E40-E43, 2015 | 173 | 2015 |
| Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis S Rule, M Dreyling, A Goy, G Hess, R Auer, B Kahl, JÁ Hernández-Rivas, ... Haematologica 104 (5), e211, 2019 | 152 | 2019 |
| SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status L Lopez-Corral, ME Sarasquete, S Beà, R García-Sanz, MV Mateos, ... Leukemia 26 (12), 2521-2529, 2012 | 128 | 2012 |
| Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis F Cavazzini, JA Hernandez, A Gozzetti, A Russo Rossi, C De Angeli, ... British journal of haematology 142 (4), 529-537, 2008 | 125 | 2008 |
| A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia JÁ Hernández, AE Rodríguez, M González, R Benito, C Fontanillo, ... haematologica 94 (3), 364, 2009 | 108 | 2009 |
| Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma ML Wang, W Jurczak, M Jerkeman, J Trotman, PL Zinzani, D Belada, ... New England Journal of Medicine 386 (26), 2482-2494, 2022 | 106 | 2022 |
| Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and … B Paiva, MC Montes, R García-Sanz, EM Ocio, J Alonso, N de Las Heras, ... Leukemia 28 (1), 166-173, 2014 | 99 | 2014 |
| Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients B Paiva, NC Gutierrez, X Chen, MB Vidriales, MÁ Montalbán, L Rosinol, ... Leukemia 26 (8), 1862-1869, 2012 | 93 | 2012 |
| The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients B Paiva, MB Vidriales, G Mateo, JJ Perez, MA Montalbán, A Sureda, ... Blood, The Journal of the American Society of Hematology 114 (20), 4369-4372, 2009 | 91 | 2009 |
| Detection of tumor cells in the peripheral blood of nonleukemic patients with B-cell lymphoma: analysis of “clonal excess” FS Ligler, RG Smith, JR Kettman, JA Hernandez, JB Himes, ES Vitetta, ... Blood 55 (5), 792-801, 1980 | 88 | 1980 |
| Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study … JM Ribera, O García, C Grande, J Esteve, A Oriol, J Bergua, ... Cancer 119 (9), 1660-1668, 2013 | 87 | 2013 |
| Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL JT Navarro, JA Hernández, JM Ribera, JM Sancho, A Oriol, M Pujol, ... Haematologica 83 (11), 998-1000, 1998 | 85 | 1998 |
